A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
These early structural studies were not followed up until recent years with the renewed interest in bottromycin. The structure was confirmed in the 1980s and 1990s to be a cyclic iminopeptide based on NMR studies, with a linear side chain connected to the macrocycle via an amidine linkage. Its absolute stereochemistry, however, was not characterized until 2009. Stereochemistry at carbon 18 and 25 was proposed by comparing predicted conformers obtained using molecular dynamics to experimental constraints obtained through NMR experiments. Stereochemistry at carbon 43 was confirmed by comparing 1H NMR of authentic hydrolysis product to a chemically synthesized sample of the same fragment. Finally, optical rotation, 1H NMR, and HRMS experiments of chemically synthesized bottromycin matched that of biologically produced bottromycin. The three-dimensional solution structure of bottromycin A2 was solved by NMR in 2012. The overall structure was obtained with good resolution (RMSD 0.74±0.59 Å), with a RMSD of 0.09±0.06 Å for the macrocycle. In this study, it was proposed that the methylated proline residue contributed to the restricted conformation of the macrocycle. The methylated proline and β-OMe alanine residues were found to be on the same face of bottroymycin A2 and it was suggested that this characteristic contributed to binding of bottromycin to the ribosomal A site.
5-HT1A receptor (as partial or full agonists) 5-HT2A receptor (as inverse agonists) D2 receptor (as antagonists or partial agonists) α1-adrenergic receptor (as antagonists) α2-adrenergic receptor (as antagonists) Actions at D4, 5-HT2C, 5-HT7, and sigma receptors have also been shown for some azapirones. While some of the listed properties such as 5-HT2A and D2 blockade may be useful in certain indications such as in the treatment of schizophrenia (as with perospirone and tiospirone), all of them except 5-HT1A agonism are generally undesirable in anxiolytics and only contribute to side effects. As a result, further development has commenced to bring more selective of anxiolytic agents to the market. An example of this initiative is gepirone, which was recently approved after completing clinical trials in the United States for the treatment of major depression and generalized anxiety disorder. Another example is tandospirone which has been licensed in Japan for the treatment of anxiety and as an augmentation to antidepressants for depression. 5-HT1A receptor partial agonists have demonstrated efficacy against depression in rodent studies and human clinical trials. Unfortunately, however, their efficacy is limited and they are only relatively mild antidepressants. Instead of being used as monotherapy treatments, they are more commonly employed as augmentations to serotonergic antidepressants like the SSRIs.
=== Fertilizer === Hydrolyzing a protein improves the digestibility not only for animals, but also for soil microbes. As a result, it becomes useful as a fertilizer providing nitrogen and potentially also sulfur. Hydrolyzed keratin from chicken feather is the most common type, though other kinds of waste proteins (e.g. waste wool, waste fish) are also re-used this way. Hydrolyzed protein fertilizer is considered an organic fertilizer. It contains a high amount of available nitrogen, and unlike unhydrolyzed feather meal, tends to release the nitrogen quickly. It helps the growth of soil microbes and improves soil quality.
is a quotient of activity coefficients. To avoid the complications involved in using activities, dissociation constants are determined, where possible, in a medium of high ionic strength, that is, under conditions in which
Sources: en.wikipedia.org
== Species distribution == Across vertebrates, four paralogous TCAPs (TCAP-1–4) exhibit structural similarity to corticotropin-releasing hormone (CRH) and other secretin-family peptides and have been shown in rodent and non-mammalian models to exert anxiolytic-like effects, modulate glucose and energy homeostasis, and participate in broader tissue-specific signaling, highlighting TCAPs as evolutionarily conserved peptides.
In 1738, Swiss physicist and mathematician Daniel Bernoulli postulated that the pressure of gases and heat were both caused by the underlying motion of molecules. Using his model he could predict the ideal gas law at constant temperature and suggested that the temperature was proportional to the velocity of the particles. This success was not followed up, in part because the then new tools of calculus allowed more progress using continuous models for gases. James Clerk Maxwell, a vocal proponent of atomism, revived the kinetic theory in 1860 and 1867. His key insight was that the velocity of particles in a gas would vary around an average value, introducing the concept of a distribution function. In the late 1800s, Ludwig Boltzmann used atomic models to apply kinetic theory to thermodynamics especially the second law relating to entropy. Boltzmann defended the atomistic hypothesis against major detractors from the time like Ernst Mach or energeticists like Wilhelm Ostwald, who considered that energy was the elementary quantity of reality. However an atomic model was not essential for the development of theory of thermodynamics. This became clear when Josiah Willard Gibbs introduced statistical mechanics in his 1902 book Elementary Principles in Statistical Mechanics. His logical and formal development of a new approach specifically avoided requiring an atomic hypothesis. Albert Einstein independently developed an approach similar to Gibbs, but with a completely different aim: Einstein set out to find a way to verify the atomic hypothesis through the kinetic theory.
Ethanol (alcohol) is first converted into acetaldehyde, consuming NAD+ twice, before being converted into acetate. The acetate is then converted into acetyl-CoA. When alcohol is consumed in small quantities, the NADH/NAD+ ratio remains in balance enough for the acetyl-CoA to be used by the Krebs cycle for oxidative phosphorylation. However, even moderate amounts of alcohol (1-2 drinks) results in more NADH than NAD+, which inhibits oxidative phosphorylation. When the NADH/NAD+ ratio is disrupted (far more NADH than NAD+), this is called pseudohypoxia. The Krebs cycle needs NAD+ as well as oxygen, for oxidative phosphorylation. Without sufficient NAD+, the impaired aerobic metabolism mimics hypoxia (insufficient oxygen), resulting in excessive use of anaerobic glycolysis and a disrupted pyruvate/lactate ratio (low pyruvate, high lactate). The conversion of pyruvate into lactate produces NAD+, but only enough to maintain anaerobic glycolysis. In chronic excessive alcohol consumption (alcoholism), the microsomal ethanol oxidizing system (MEOS) is used in addition to alcohol dehydrogenase.
Sources: en.wikipedia.org
In 1977 an animated musical television film of The Hobbit was made by Rankin-Bass, and in 1980 they produced the animated musical television film The Return of the King, which covered some of the portions of The Lord of the Rings that Bakshi was unable to complete. From 2001 to 2003 New Line Cinema released The Lord of the Rings as a trilogy of live-action films that were filmed in New Zealand and directed by Peter Jackson. The series was successful, performing extremely well commercially and winning numerous Oscars. From 2012 to 2014 Warner Bros. and New Line Cinema released The Hobbit, a series of three films based on The Hobbit, with Peter Jackson serving as executive producer, director, and co-writer. In 2017 Amazon acquired the global television rights to The Lord of the Rings, for a series of new stories set before The Fellowship of the Ring.
Kant thus concluded that even if people did not desire to leave anarchy, they ought to as a matter of duty to abide by universal laws. Kant also gave a short definition of anarchy in contrast to other forms of society:
== External links == "Relaxin Family Peptide Receptors: RXFP3". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.